Date: 2014-10-08
Type of information: Nomination
Compound: member of the supervisory board
Company: Bayer (Germany)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 8, 2014, the Local Court of Cologne has appointed Professor Otmar D. Wiestler (57) to the Supervisory Board of Bayer AG. He replaces Dr. Klaus Kleinfeld (56), who left the Supervisory Board at his own request effective September 30, 2014, in order to concentrate on his other offices and honorary posts, some of which are in the United States. Since January 1, 2004, Wiestler has been Chairman of the Management Board and Scientific Director of the German Cancer Research Center (DKFZ) in Heidelberg, Germany. Also since 2004 he has been Chairman of the Advisory Committee and a member of the board of German Cancer Aid. From 2007 to 2012, he was a Vice-President in the Executive Committee of the Helmholtz Association.
- Kleinfeld has been Chief Executive Officer of U.S. metals and technology company Alcoa Inc. since May 2008. He joined the Supervisory Board of Bayer AG on April 29, 2005.
Financial terms:
Latest news:
Is general: Yes
